ISTO Technologies Inc. announced an agreement with Zimmer Holdings Inc. giving ISTO full control of the DeNovo ET Engineered Tissue program, an engineered cartilage implant intended to repair cartilage defects in the knee.
According to a company press release, under the terms of the agreement, any rights and responsibilities previously held by Zimmer related to ISTO and the program have been cancelled. The product has been renamed RevaFlex and will proceed independently with further development of the program though a phase 3 clinical program.
In addition, under the terms of the termination of the collaboration agreement, ISTO will transfer ownership of DeNovo NT, a particulated juvenile cartilage allograft tissue implant product, to Zimmer.
